Journal of Clinical Oncology
Articles in this Issue
Design and implementation of a patient-centric expanded access program with cretostimogene grenadenorepvec in non-muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin.
TPS897 Background: Current guidelines recommend radical cystectomy for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bla...
Extended multi-centre review of adjuvant pembrolizumab for renal cell carcinoma.
458 Background: In patients at increased risk of recurrence following surgical resection of RCC, adjuvant pembrolizumab ha...
Phase 1B/2 study of combination <sup>177</sup> Lu girentuximab plus cabozantinib and nivolumab in treatment-naïve patients with advanced clear cell RCC.
TPS582 Background: Complete response (CR) remains a rare outcome in advanced clear cell renal cell carcinoma (ccRCC). The...
Induction enfortumab vedotin plus pembrolizumab followed by maintenance pembrolizumab in first-line metastatic urothelial carcinoma (IMPROEV).
TPS893 Background: Enfortumab vedotin plus pembrolizumab (EV/P) is the preferred first-line regimen for metastatic urothel...
Real-world survival outcomes with single-agent erdafitinib (Erda) in patients (pts) with advanced urothelial carcinoma (aUC) based on line (L) of therapy and prior enfortumab vedotin (EV) treatment (Rx).
694 Background: Erda, a pan fibroblast growth factor receptor (FGFR) inhibitor, has been approved since 2019 for pts with...
Preoperative CT radiomics–deep learning signature for lymphovascular invasion in bladder cancer: External validation and clinical utility.
857 Background: Lymphovascular invasion (LVI) critically guides neoadjuvant therapy, cystectomy timing, and surveillance i...
Real-world outcomes of clear-cell renal cell carcinoma (ccRCC) patients treated with belzutifan stratified by von Hippel-Lindau (VHL) status.
475 Background: Belzutifan is a HIF-2a inhibitor with demonstrated efficacy in ccRCC associated with VHL syndrome. Belzuti...
Histopathologic and spatial transcriptomic analyses of en bloc resections of de novo and recurrent bladder tumors.
864 Background: En bloc transurethral resection of bladder tumors (ERBT) is a safe and effective treatment for non-muscle...
The application of 5.0-Tesla non-enhanced MRI in the preoperative assessment of renal tumors.
426 Background: To assess the utility of 5.0-Tesla non-enhanced magnetic resonance imaging (5T NE MRI) for preoperative ev...
Front-line (1L) treatment and recurrence patterns among patients with high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with papillary carcinoma (PAP) or carcinoma in situ (CIS) following bacillus Calmette-Guérin (BCG) or other intravesical therapies (IVT).
708 Background: HR-NMIBC carries substantial burden and high recurrence risk. Guidelines recommend BCG as 1L therapy, with...
Expansion and characterization of tumor-infiltrating lymphocytes from primary and metastatic immune checkpoint inhibitor-exposed renal cell carcinoma tumors.
548 Background: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has demonstrated efficacy in patien...
External validation of AI age discrepancy as a measure of frailty in kidney tumor patients.
427 Background: Our team previously introduced AI Age Discrepancy, a novel parameter for quantifying frailty and postopera...
A phase 2 study of gemcitabine plus carboplatin as second-line therapy after prior enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma.
TPS901 Background: Urothelial carcinoma (UC) is a common malignancy of older adults, associated with poor survival once me...
Prediction of socioeconomic disadvantage using AI analysis of CT imaging in kidney cancer patients.
428 Background: Socioeconomic status (SES) has been linked to higher rates of mortality after major urologic surgery; howe...
Association of serum kidney injury molecule-1 with treatment response and survival in metastatic renal cell carcinoma.
534 Background: First-line immune checkpoint inhibitor (IO)-based therapies have improved the prognosis of patients with m...
Acute and chronic GU/GI toxicity after conventional versus hypofractionated radiotherapy (HFRT) with concurrent chemotherapy for muscle-invasive bladder cancer: A multi-institutional analysis by CURE-BC - Consortium for Urothelial Radiation Excellence – Bladder Cancer.
718 Background: HFRT is increasingly used as a bladder-preserving regimen for muscle-invasive bladder cancer (MIBC), altho...
Prospective multicenter development and external validation of a narrow-band imaging based prediction model for malignancy risk in bladder lesions.
644 Background: White-light cystoscopy lacks specificity, driving unnecessary resections. NBI improves visibility but rais...
HER2 and nectin-4 IHC expression and clinical outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.
827 Background: Enfortumab vedotin and pembrolizumab (EV/P) is the standard of care for metastatic urothelial carcinoma (U...
Efficacy and safety of belzutifan in patients with metastatic clear cell renal cell carcinoma (mccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
479 Background: Belzutifan, a hypoxia-inducible factor 2α inhibitor (HIF2i), has been recently approved for the management...
Circulating tumor DNA dynamics as a predictive biomarker of response and survival in metastatic urothelial carcinoma treated with enfortumab vedotin and pembrolizumab.
860 Background: On treatment biomarkers that connect molecular clearance to clinical outcomes are needed in metastatic uro...
Duplex-Seq derived urinary cell-free DNA of Lynch syndrome patients with upper tract urothelial carcinoma.
838 Background: There is a critical need to develop urinary biomarkers for upper tract urothelial carcinoma (UTUC), especi...
Trends in overall survival with evolving systemic therapies for metastatic non–clear cell RCC: An analysis over two decades.
474 Background: Metastatic non–clear cell renal cell carcinoma (nccRCC) is a rare, heterogeneous disease historically unde...
Germline DNA repair gene (gDRG) variants in BCG un-responsive patients: A potential genetic implication for risk stratification and target therapy.
808 Background: The introduction of the “BCG-unresponsive” definition by the U.S. Food and Drug Administration (FDA) has p...
The molecular mechanism of lymph node metastasis driven by B lymphocyte FOXO1 palmitoylation induced by ACSL5 deficiency in bladder cancer cells.
835 Background: Bladder cancer (BLCA) is one of the most common malignancies of the urinary system, with muscle-invasive b...
Subclinical hepatic injury and risk of nonalcoholic steatohepatitis after adjuvant systemic therapy in early-stage testicular cancer survivors.
607 Background: Patients with early-stage TGCT have an excellent long-term prognosis. Guidelines recommend active surveill...